Drug Trial Radar · NCT07708181
A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Aug 2, 2026
Primary completion
Aug 11, 2027
Study completion Apr 19, 2028
Sponsor
- Lead sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment
Conditions
- Gout Arthritis
Interventions
SSGJ-613 100 mg Q12WDrug
Participants will receive one s.c. injection of SSGJ-613 on Day 1、W12
SSGJ-613 200 mg Q12WDrug
Participants will receive one s.c. injection of SSGJ-613 on Day 1、W12
SSGJ-613 100 mg Q4WDrug
Participants will receive one s.c. injection of SSGJ-613 on Day 1、W4、W8、W12
Colchicine 0.5 mgDrug
Participants will receive 0.5mg bid Colchicine for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Numbers of acute gout flaresTime frame: 24 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.